NCT07087626 COPD Assessment Test Score and Perioperative Risk in COPD
| NCT ID | NCT07087626 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Erzurum City Hospital |
| Condition | COPD |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-08-15 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2025-08-15 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational cohort study is to evaluate whether the COPD Assessment Test (CAT) score can predict the risk of perioperative respiratory complications in patients aged 40 to 70 years with diagnosed Chronic Obstructive Pulmonary Disease (COPD), undergoing elective surgical procedures lasting no longer than 150 minutes. The main questions it aims to answer are: * Is there a statistically significant association between preoperative CAT scores and the incidence of intraoperative and early postoperative respiratory complications in COPD patients? * Can the CAT score be effectively used as a preoperative risk stratification tool to guide anesthetic and surgical decision-making? Researchers will compare two patient groups based on CAT scores: those with CAT \<10 and those with CAT ≥10 to determine whether higher CAT scores are associated with an increased incidence of perioperative respiratory complications. Participants will: * Complete the CAT questionnaire during the preoperative evaluation * Undergo elective surgery with an expected duration of ≤150 minutes * Be monitored intraoperatively for bronchospasm, oxygen desaturation, and ventilation difficulty * Be monitored postoperatively (within the first 72 hours) for hypoxemia, reintubation, bronchospasm episodes, postoperative pneumonia, intensive care unit (ICU) admission, and length of hospital stay * Have perioperative clinical data collected and analyzed for comparative outcomes between CAT score subgroups
Eligibility Criteria
Inclusion Criteria: * Patients aged between 40 and 70 years * Diagnosed with stable-stage Chronic Obstructive Pulmonary Disease (COPD) according to GOLD criteria * Scheduled for elective surgical intervention * Classified as ASA Physical Status II or III according to the American Society of Anesthesiologists (ASA) * Planned for postoperative follow-up and eligible for at least 72 hours of observation * Undergoing surgery with an expected duration of at least 150 minutes * Willing to participate voluntarily in the study Exclusion Criteria: * Patients younger than 40 years or older than 70 years * History of COPD exacerbation within the past 4 weeks * Presence of severe cardiac failure (EF \<30%), end-stage renal disease, or active malignancy * Neurological disorders or cognitive impairments * Requirement for invasive mechanical ventilation in the preoperative period * Altered consciousness or any condition preventing completion of forms before anesthesia * Undergoing surgery with an expected duration longer than 150 minutes * Unwillingness to participate in the study voluntarily
Contact & Investigator
Mehmet S Orbak
PRINCIPAL INVESTIGATOR
Erzurum City Hospital
Frequently Asked Questions
Who can join the NCT07087626 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 70 Years, studying COPD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07087626 currently recruiting?
Yes, NCT07087626 is actively recruiting participants. Contact the research team at sercanorbak@gmail.com for enrollment information.
Where is the NCT07087626 trial being conducted?
This trial is being conducted at Erzurum, Turkey (Türkiye).
Who is sponsoring the NCT07087626 clinical trial?
NCT07087626 is sponsored by Erzurum City Hospital. The principal investigator is Mehmet S Orbak at Erzurum City Hospital. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.